Bayer hemophilia A and prostate cancer meds cleared in Japan

• The Japanese Ministry of Health, Labor and Welfare approves two new products from Bayer (OTCPK:BAYRY):
• Kovaltry, a full-length recombinant factor VIII for the treatment of hemophilia A, already commercially available in the U.S. EU and Canada.
• Xofigo (radium-223 dichloride, radium-223), an alpha-particle-emitting anti-tumor pharmaceutical for the treatment of castration-resistant prostate cancer, currently marketed in over 40 countries, including the U.S. and countries of the EU.